Please use this identifier to cite or link to this item:
|Title:||Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia||Authors:||Zambon, Alberto||Keywords:||Cardiovascular risk;Diabetic dyslipidaemia;Fenofibrate;Low-density lipoprotein cholesterol;Non-high-density lipoprotein cholesterol;Omega-3 fatty acids;Statins;Triglycerides||Keywords Plus:||COMBINATION LIPID THERAPY;CORONARY-HEART-DISEASE;NON-HDL CHOLESTEROL;TREATED PATIENTS;RISK;TRIGLYCERIDES;PREVENTION;EVENTS;ATORVASTATIN;SIMVASTATIN||Issue Date:||1-Jan-2020||Publisher:||ENDOCRINOLOGY RESEARCH CENTRE||Journal:||Diabetes Mellitus||Abstract:||
© Endocrinology Research Centre, 2020. Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderately elevated levels of low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C). Statin therapy to reduce LDL-C levels is the mainstay of treatment practice to reduce CV risk. However, despite achieving targets for LDL-C, patients with diabetic dyslipidaemia remain at a high risk of residual CV events. Hence there is a need to target other components (i.e. elevated TGs) of the atherogenic dyslipidaemia that are not affected by treatment with statins. This review highlights the clinical benefits of using non-HDL-C, a single marker that includes all atherogenic lipoproteins, as a leading treatment target to reduce the residual CV risk.
|Appears in Collections:||Articles|
Show full item record
Page view(s) 15
checked on Oct 23, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.